Baroreflex activation therapy in advanced heart failure: A long-term follow-up.

ABSTRACT:

Aims

Baroreceptor activation therapy (BAT) is a promising new treatment strategy for patients with heart failure with reduced ejection fraction (HFrEF). It provides symptomatic relief, improvement in left ventricular function and reduction of cardiac biomarkers. Data regarding the long-term effect of BAT on HFrEF are scarce. This retrospective, monocentric study aimed to assess long-term outcome in patients who underwent BAT.

Methods

Patients with HFrEF who received BAT at Hannover Medical School between 2014 and 2023 were followed until the latest available follow-up. Symptom burden, echocardiography and laboratory testing were assessed before BAT implantation and in subsequent follow-ups.

Results

Twenty-three patients (mean age 66 ± 10 years, 83% male) with HFrEF we

SUBMITTER: Wang D 

PROVIDER: S-EPMC11769634 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature